Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|September 15, 2022
People and Business News — 9/22
Advertisement
People News
Clinovo appointed Nandish Poluru as Chief Executive.
Allucent, announced the appointment of Steffany Cox as its chief marketing officer.
Susan Robbins joined HeartcoR Solutions as its director of training. Additionally, Michelle Mills has joined the organization as director of ECG analysis and quality control.
MMS Holdings Inc. announced the appointment of Kelly J. Hill to Chief Strategy Officer.
Florence Healthcare has hired Kristin Surdam, who will lead the company’s thought leadership team and efforts to engage sponsors and contract research organizations, and Gunnar Esiason, who will lead patient-facing strategies.
Elligo Health Research announced Chief Scientific Officer Rebecca Kush, PhD, was recently elected Chair of the Vulcan Advisory Council.
Promontory Therapeutics Inc. announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations.
Parexel promoted Peyton Howell to the newly created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
Business News
Strata Oncology, Inc. announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
Recognition
Jumo Health announced it has made Inc. Magazine’s Inc. 5000 list.
LaQuinta Jernigan, Chief Operating Officer for mdgroup, has been recognized as one of 100 most inspiring people in life sciences.
WCG’s Vice President, Patient Advocacy and Clinical Research Diversity, Lori Abrams, has been named a Diversity, Equity, and Inclusion Champion.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5